Skip to main content
Top
Published in: Endocrine 2/2017

01-02-2017 | Original Article

Heterogeneity in glucose response curves during an oral glucose tolerance test and associated cardiometabolic risk

Authors: Adam Hulman, Rebecca K. Simmons, Dorte Vistisen, Adam G. Tabák, Jacqueline M. Dekker, Marjan Alssema, Femke Rutters, Anitra D. M. Koopman, Thomas P. J. Solomon, John P. Kirwan, Torben Hansen, Anna Jonsson, Anette Prior Gjesing, Hans Eiberg, Arne Astrup, Oluf Pedersen, Thorkild I. A. Sørensen, Daniel R. Witte, Kristine Færch

Published in: Endocrine | Issue 2/2017

Login to get access

Abstract

We aimed to examine heterogeneity in glucose response curves during an oral glucose tolerance test with multiple measurements and to compare cardiometabolic risk profiles between identified glucose response curve groups. We analyzed data from 1,267 individuals without diabetes from five studies in Denmark, the Netherlands and the USA. Each study included between 5 and 11 measurements at different time points during a 2-h oral glucose tolerance test, resulting in 9,602 plasma glucose measurements. Latent class trajectories with a cubic specification for time were fitted to identify different patterns of plasma glucose change during the oral glucose tolerance test. Cardiometabolic risk factor profiles were compared between the identified groups. Using latent class trajectory analysis, five glucose response curves were identified. Despite similar fasting and 2-h values, glucose peaks and peak times varied greatly between groups, ranging from 7–12 mmol/L, and 35–70 min. The group with the lowest and earliest plasma glucose peak had the lowest estimated cardiovascular risk, while the group with the most delayed plasma glucose peak and the highest 2-h value had the highest estimated risk. One group, with normal fasting and 2-h values, exhibited an unusual profile, with the highest glucose peak and the highest proportion of smokers and men. The heterogeneity in glucose response curves and the distinct cardiometabolic risk profiles may reflect different underlying physiologies. Our results warrant more detailed studies to identify the source of the heterogeneity across the different phenotypes and whether these differences play a role in the development of type 2 diabetes and cardiovascular disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference K. Faerch, A. Hulman, T.P. Solomon, Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness. Curr. Diabetes Rev. 12, 30–41 (2016)CrossRefPubMed K. Faerch, A. Hulman, T.P. Solomon, Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness. Curr. Diabetes Rev. 12, 30–41 (2016)CrossRefPubMed
2.
go back to reference K. Faerch, D.R. Witte, A.G. Tabak, L. Perreault, C. Herder, E.J. Brunner, M. Kivimaki, D. Vistisen, Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes Endocrinol 1, 43–51 (2013)CrossRefPubMed K. Faerch, D.R. Witte, A.G. Tabak, L. Perreault, C. Herder, E.J. Brunner, M. Kivimaki, D. Vistisen, Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes Endocrinol 1, 43–51 (2013)CrossRefPubMed
3.
go back to reference M.A. Abdul-Ghani, V. Lyssenko, T. Tuomi, R.A. Defronzo, L. Groop, The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab. Res. Rev. 26, 280–286 (2010)CrossRefPubMed M.A. Abdul-Ghani, V. Lyssenko, T. Tuomi, R.A. Defronzo, L. Groop, The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab. Res. Rev. 26, 280–286 (2010)CrossRefPubMed
4.
go back to reference M.A. Abdul-Ghani, K. Williams, R.A. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30, 1544–1548 (2007)CrossRefPubMed M.A. Abdul-Ghani, K. Williams, R.A. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30, 1544–1548 (2007)CrossRefPubMed
5.
go back to reference A. Alyass, P. Almgren, M. Akerlund, J. Dushoff, B. Isomaa, P. Nilsson, T. Tuomi, V. Lyssenko, L. Groop, D. Meyre, Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia 58, 87–97 (2015)CrossRefPubMed A. Alyass, P. Almgren, M. Akerlund, J. Dushoff, B. Isomaa, P. Nilsson, T. Tuomi, V. Lyssenko, L. Groop, D. Meyre, Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia 58, 87–97 (2015)CrossRefPubMed
6.
go back to reference M. Bergman, A. Chetrit, J. Roth, R. Dankner, Dysglycemia and long-term mortality: observations from the Israel study of glucose intolerance, obesity and hypertension. Diabetes Metab. Res. Rev. 31, 368–375 (2015)CrossRefPubMed M. Bergman, A. Chetrit, J. Roth, R. Dankner, Dysglycemia and long-term mortality: observations from the Israel study of glucose intolerance, obesity and hypertension. Diabetes Metab. Res. Rev. 31, 368–375 (2015)CrossRefPubMed
7.
go back to reference R. Jagannathan, M.A. Sevick, H. Li, D. Fink, R. Dankner, A. Chetrit, J. Roth, M. Bergman, Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting. Endocrine 52, 172–175 (2016)CrossRefPubMed R. Jagannathan, M.A. Sevick, H. Li, D. Fink, R. Dankner, A. Chetrit, J. Roth, M. Bergman, Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting. Endocrine 52, 172–175 (2016)CrossRefPubMed
8.
go back to reference M. Kanauchi, K. Kimura, K. Kanauchi, Y. Saito, Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int. J. Clin. Pract. 59, 427–432 (2005)CrossRefPubMed M. Kanauchi, K. Kimura, K. Kanauchi, Y. Saito, Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int. J. Clin. Pract. 59, 427–432 (2005)CrossRefPubMed
9.
go back to reference K. Faerch, A. Vaag, J.J. Holst, C. Glumer, O. Pedersen, K. Borch-Johnsen, Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 51, 853–861 (2008)CrossRefPubMed K. Faerch, A. Vaag, J.J. Holst, C. Glumer, O. Pedersen, K. Borch-Johnsen, Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 51, 853–861 (2008)CrossRefPubMed
10.
go back to reference J.M. Rijkelijkhuizen, C.J. Girman, A. Mari, M. Alssema, T. Rhodes, G. Nijpels, P.J. Kostense, P.P. Stein, E.M. Eekhoff, R.J. Heine, J.M. Dekker, Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. Diabetes Res. Clin. Pract. 83, 280–288 (2009)CrossRefPubMed J.M. Rijkelijkhuizen, C.J. Girman, A. Mari, M. Alssema, T. Rhodes, G. Nijpels, P.J. Kostense, P.P. Stein, E.M. Eekhoff, R.J. Heine, J.M. Dekker, Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. Diabetes Res. Clin. Pract. 83, 280–288 (2009)CrossRefPubMed
11.
go back to reference T.P. Solomon, S.K. Malin, K. Karstoft, S.H. Knudsen, J.M. Haus, M.J. Laye, J.P. Kirwan, Association between cardiorespiratory fitness and the determinants of glycemic control across the entire glucose tolerance continuum. Diabetes Care. 38, 921–929 (2015)CrossRefPubMedPubMedCentral T.P. Solomon, S.K. Malin, K. Karstoft, S.H. Knudsen, J.M. Haus, M.J. Laye, J.P. Kirwan, Association between cardiorespiratory fitness and the determinants of glycemic control across the entire glucose tolerance continuum. Diabetes Care. 38, 921–929 (2015)CrossRefPubMedPubMedCentral
12.
go back to reference L.H. Larsen, A.P. Gjesing, T.I. Sorensen, Y.H. Hamid, S.M. Echwald, S. Toubro, E. Black, A. Astrup, T. Hansen, O. Pedersen, Mutation analysis of the preproghrelin gene: no association with obesity and type 2 diabetes. Clin. Biochem. 38, 420–424 (2005)CrossRefPubMed L.H. Larsen, A.P. Gjesing, T.I. Sorensen, Y.H. Hamid, S.M. Echwald, S. Toubro, E. Black, A. Astrup, T. Hansen, O. Pedersen, Mutation analysis of the preproghrelin gene: no association with obesity and type 2 diabetes. Clin. Biochem. 38, 420–424 (2005)CrossRefPubMed
13.
go back to reference A.P. Gjesing, C.T. Ekstrom, H. Eiberg, S.A. Urhammer, J.J. Holst, O. Pedersen, T. Hansen, Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits. Diabetologia 55, 1338–1345 (2012)CrossRefPubMed A.P. Gjesing, C.T. Ekstrom, H. Eiberg, S.A. Urhammer, J.J. Holst, O. Pedersen, T. Hansen, Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits. Diabetologia 55, 1338–1345 (2012)CrossRefPubMed
14.
go back to reference T. Jorgensen, K. Borch-Johnsen, T.F. Thomsen, H. Ibsen, C. Glumer, C. Pisinger, A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur. J. Cardiovasc. Prev. Rehabil. 10, 377–386 (2003)CrossRefPubMed T. Jorgensen, K. Borch-Johnsen, T.F. Thomsen, H. Ibsen, C. Glumer, C. Pisinger, A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur. J. Cardiovasc. Prev. Rehabil. 10, 377–386 (2003)CrossRefPubMed
15.
go back to reference L. Andersen, B. Dinesen, P.N. Jorgensen, F. Poulsen, M.E. Roder, Enzyme immunoassay for intact human insulin in serum or plasma. Clin. Chem. 39, 578–582 (1993)PubMed L. Andersen, B. Dinesen, P.N. Jorgensen, F. Poulsen, M.E. Roder, Enzyme immunoassay for intact human insulin in serum or plasma. Clin. Chem. 39, 578–582 (1993)PubMed
17.
go back to reference R.M. Conroy, K. Pyorala, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, D. De Bacquer, P. Ducimetiere, P. Jousilahti, U. Keil, I. Njolstad, R.G. Oganov, T. Thomsen, H. Tunstall-Pedoe, A. Tverdal, H. Wedel, P. Whincup, L. Wilhelmsen, I.M. Graham, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart. J. 24, 987–1003 (2003)CrossRefPubMed R.M. Conroy, K. Pyorala, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, D. De Bacquer, P. Ducimetiere, P. Jousilahti, U. Keil, I. Njolstad, R.G. Oganov, T. Thomsen, H. Tunstall-Pedoe, A. Tverdal, H. Wedel, P. Whincup, L. Wilhelmsen, I.M. Graham, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart. J. 24, 987–1003 (2003)CrossRefPubMed
18.
go back to reference M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 22, 1462–1470 (1999)CrossRefPubMed M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 22, 1462–1470 (1999)CrossRefPubMed
19.
go back to reference D.I. Phillips, P.M. Clark, C.N. Hales, C. Osmond, Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet. Med. 11, 286–292 (1994)CrossRefPubMed D.I. Phillips, P.M. Clark, C.N. Hales, C. Osmond, Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet. Med. 11, 286–292 (1994)CrossRefPubMed
20.
go back to reference R Development Core Team. R: A language and environment for statistical computing. In. R Foundation for Statistical Computing, Vienna, Austria, (2015) R Development Core Team. R: A language and environment for statistical computing. In. R Foundation for Statistical Computing, Vienna, Austria, (2015)
21.
go back to reference D. Carpenter, S. Dhar, L.M. Mitchell, B. Fu, J. Tyson, N.A.A. Shwan, F. Yang, M.G. Thomas, J.A.L. Armour, Obesity, starch digestion and amylase: association between copy number variants at human salivary (AMY1) and pancreatic (AMY2) amylase genes. Hum. Mol. Gen. 24, 3472–3480 (2015)CrossRefPubMedPubMedCentral D. Carpenter, S. Dhar, L.M. Mitchell, B. Fu, J. Tyson, N.A.A. Shwan, F. Yang, M.G. Thomas, J.A.L. Armour, Obesity, starch digestion and amylase: association between copy number variants at human salivary (AMY1) and pancreatic (AMY2) amylase genes. Hum. Mol. Gen. 24, 3472–3480 (2015)CrossRefPubMedPubMedCentral
22.
go back to reference N. Guess, L. Perreault, A. Kerege, A. Strauss, B.C. Bergman, Dietary Fatty Acids Differentially Associate with Fasting Versus 2-Hour Glucose Homeostasis: Implications for The Management of Subtypes of Prediabetes. PLoS ONE 11, e0150148 (2016)CrossRefPubMedPubMedCentral N. Guess, L. Perreault, A. Kerege, A. Strauss, B.C. Bergman, Dietary Fatty Acids Differentially Associate with Fasting Versus 2-Hour Glucose Homeostasis: Implications for The Management of Subtypes of Prediabetes. PLoS ONE 11, e0150148 (2016)CrossRefPubMedPubMedCentral
23.
go back to reference L.P. Lidegaard, A.L. Hansen, N.B. Johansen, D.R. Witte, S. Brage, T. Lauritzen, M.E. Jorgensen, D.L. Christensen, K. Faerch, Physical activity energy expenditure vs cardiorespiratory fitness level in impaired glucose metabolism. Diabetologia. 58, 2709–2717 (2015)CrossRefPubMed L.P. Lidegaard, A.L. Hansen, N.B. Johansen, D.R. Witte, S. Brage, T. Lauritzen, M.E. Jorgensen, D.L. Christensen, K. Faerch, Physical activity energy expenditure vs cardiorespiratory fitness level in impaired glucose metabolism. Diabetologia. 58, 2709–2717 (2015)CrossRefPubMed
24.
go back to reference K. Faerch, K. Borch-Johnsen, A. Vaag, T. Jorgensen, D.R. Witte, Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia 53, 858–865 (2010)CrossRefPubMed K. Faerch, K. Borch-Johnsen, A. Vaag, T. Jorgensen, D.R. Witte, Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia 53, 858–865 (2010)CrossRefPubMed
25.
go back to reference W. Rathmann, K. Strassburger, G. Giani, A. Doring, C. Meisinger, Differences in height explain gender differences in the response to the oral glucose tolerance test. Diabet. Med. 25, 1374–1375 (2008)PubMed W. Rathmann, K. Strassburger, G. Giani, A. Doring, C. Meisinger, Differences in height explain gender differences in the response to the oral glucose tolerance test. Diabet. Med. 25, 1374–1375 (2008)PubMed
26.
go back to reference C.S. Marathe, C.K. Rayner, K.L. Jones, M. Horowitz, Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36, 1396–1405 (2013)CrossRefPubMedPubMedCentral C.S. Marathe, C.K. Rayner, K.L. Jones, M. Horowitz, Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36, 1396–1405 (2013)CrossRefPubMedPubMedCentral
27.
go back to reference K. Faerch, G. Pacini, J.J. Nolan, T. Hansen, A. Tura, D. Vistisen, Impact of glucose tolerance status, sex, and body size on glucose absorption patterns during OGTTs. Diabetes Care 36, 3691–3697 (2013)CrossRefPubMedPubMedCentral K. Faerch, G. Pacini, J.J. Nolan, T. Hansen, A. Tura, D. Vistisen, Impact of glucose tolerance status, sex, and body size on glucose absorption patterns during OGTTs. Diabetes Care 36, 3691–3697 (2013)CrossRefPubMedPubMedCentral
28.
go back to reference J.J. Holst, F. Gribble, M. Horowitz, C.K. Rayner, Roles of the Gut in Glucose Homeostasis. Diabetes Care 39, 884–892 (2016)CrossRefPubMed J.J. Holst, F. Gribble, M. Horowitz, C.K. Rayner, Roles of the Gut in Glucose Homeostasis. Diabetes Care 39, 884–892 (2016)CrossRefPubMed
29.
go back to reference M. Lind, J. Tuomilehto, M. Uusitupa, O. Nerman, J. Eriksson, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, M. Peltonen, A. Pivodic, J. Lindstrom, The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. PLoS ONE 9, e109506 (2014)CrossRefPubMedPubMedCentral M. Lind, J. Tuomilehto, M. Uusitupa, O. Nerman, J. Eriksson, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, M. Peltonen, A. Pivodic, J. Lindstrom, The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. PLoS ONE 9, e109506 (2014)CrossRefPubMedPubMedCentral
30.
go back to reference Glucose tolerance and cardiovascular mortality, comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161, 397–405 (2001)CrossRef Glucose tolerance and cardiovascular mortality, comparison of fasting and 2-hour diagnostic criteria. Arch. Intern. Med. 161, 397–405 (2001)CrossRef
31.
go back to reference S. Soulimane, D. Simon, W.H. Herman, C. Lange, C.M. Lee, S. Colagiuri, J.E. Shaw, P.Z. Zimmet, D. Magliano, S.R. Ferreira, Y. Dong, L. Zhang, T. Jorgensen, J. Tuomilehto, V. Mohan, D.L. Christensen, L. Kaduka, J.M. Dekker, G. Nijpels, C.D. Stehouwer, O. Lantieri, W.Y. Fujimoto, D.L. Leonetti, M.J. McNeely, K. Borch-Johnsen, E.J. Boyko, D. Vistisen, B. Balkau, HbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysis. Diabetologia 57, 30–39 (2014)CrossRefPubMed S. Soulimane, D. Simon, W.H. Herman, C. Lange, C.M. Lee, S. Colagiuri, J.E. Shaw, P.Z. Zimmet, D. Magliano, S.R. Ferreira, Y. Dong, L. Zhang, T. Jorgensen, J. Tuomilehto, V. Mohan, D.L. Christensen, L. Kaduka, J.M. Dekker, G. Nijpels, C.D. Stehouwer, O. Lantieri, W.Y. Fujimoto, D.L. Leonetti, M.J. McNeely, K. Borch-Johnsen, E.J. Boyko, D. Vistisen, B. Balkau, HbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysis. Diabetologia 57, 30–39 (2014)CrossRefPubMed
32.
go back to reference M. Manco, S. Panunzi, D.P. Macfarlane, A. Golay, O. Melander, T. Konrad, J.R. Petrie, G. Mingrone, One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 33, 2090–2097 (2010)CrossRefPubMedPubMedCentral M. Manco, S. Panunzi, D.P. Macfarlane, A. Golay, O. Melander, T. Konrad, J.R. Petrie, G. Mingrone, One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 33, 2090–2097 (2010)CrossRefPubMedPubMedCentral
33.
go back to reference L. Perreault, S.E. Kahn, C.A. Christophi, W.C. Knowler, R.F. Hamman, Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 32, 1583–1588 (2009)CrossRefPubMedPubMedCentral L. Perreault, S.E. Kahn, C.A. Christophi, W.C. Knowler, R.F. Hamman, Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care 32, 1583–1588 (2009)CrossRefPubMedPubMedCentral
Metadata
Title
Heterogeneity in glucose response curves during an oral glucose tolerance test and associated cardiometabolic risk
Authors
Adam Hulman
Rebecca K. Simmons
Dorte Vistisen
Adam G. Tabák
Jacqueline M. Dekker
Marjan Alssema
Femke Rutters
Anitra D. M. Koopman
Thomas P. J. Solomon
John P. Kirwan
Torben Hansen
Anna Jonsson
Anette Prior Gjesing
Hans Eiberg
Arne Astrup
Oluf Pedersen
Thorkild I. A. Sørensen
Daniel R. Witte
Kristine Færch
Publication date
01-02-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1126-z

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.